Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of Jun26, CG Oncology's earnings power value is $11.56. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
CG Oncology (NAS:CGON) Earnings Power Value (EPV) Explanation
Assumption: Current profitability is sustainable.
Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.
Be Aware
Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.
CG Oncology Earnings Power Value (EPV) Related Terms
CG Oncology Earnings Power Value (EPV) Historical Data
* Premium members only.
The historical data trend for CG Oncology's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGON vs LGND, XENE, PTCT: Earnings Power Value (EPV) Comparison
For the Biotechnology subindustry, CG Oncology's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology Earnings Power Value (EPV) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where CG Oncology's Earnings Power Value (EPV) falls into.
CG Oncology Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
What does a Earnings Power Value (EPV) of $11.56 mean?
CG Oncology (CGON) has a Earnings Power Value (EPV) of $11.56 as of Jun26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on CG Oncology and its competitors.
Is CG Oncology's Earnings Power Value (EPV) too high?
CG Oncology's current Earnings Power Value (EPV) is $11.56. Overall, CG Oncology has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Earnings Power Value (EPV) compare to LGND and XENE?
CG Oncology's Earnings Power Value (EPV) of $11.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on CG Oncology and its competitors. CG Oncology's current Earnings Power Value (EPV) is $11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
Based on GuruFocus' analysis, CG Oncology (CGON) is currently considered Possible Value Trap. The stock's GF Value™ is $139.19, compared to a current price of $76.56 — trading 45% below its estimated fair value. The current Earnings Power Value (EPV) is $11.56. CG Oncology's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For CG Oncology (CGON), the current Earnings Power Value (EPV) is $11.56 as of Jun26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CG Oncology (CGON) Overvalued in 2026?
Based on GuruFocus' analysis, CG Oncology stock appears to be undervalued.
The current stock price of $76.56 is trading 45% below its estimated GF Value™ of $139.19.
GuruFocus considers CG Oncology to be Possible Value Trap.
Key valuation signals for CGON:
Earnings Power Value (EPV): $11.56
GF Value™: $139.19 vs. price of $76.56 (45% below fair value)
No single metric tells the full story. See the CGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
30GF Score
Get the complete analysis for CGON
Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGON has been successfully added to your 
